ChantrelF., EnacheI., BouillerM., KolbI., KunzK., PetitjeanP., MoulinB., HannedoucheT.Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant1999; 14: 129–36.
2.
SzetoC.C., WongT.Y., ChowK.M., LeungC.B., LawM.C., WangA.Y., LuiS.F., LiP.K.T.The impact of dialysis adequacy on the mortality and morbidity of anuric Chinese patients receiving continuous ambulatory peritoneal dialysis. J Am Soc Nephrol2001; 12: 355–60.
3.
LiP.K.T., SzetoC.C.Adequacy targets of peritoneal dialysis in the Asian population. Perit Dial Int2001; 21(suppl 3): S378–83.
4.
LiP.K.T., ChowK.M.The cost barrier of peritoneal dialysis in the developing world - An Asian perspective. Perit Dial Int2001; 21(suppl 3): S307–13.
5.
ObradorG.T., RuthazerR., AroraP., KauszA.T., PereiraB.J.Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol1999; 10: 1793–800.
6.
WuM.S., YuC.C., YangC.W., WuC.H., HaungF.Y., HongJ.J., Fan ChiangC.Y., HuangC.C., LeuM.L.Poor pre-dialysis glycemic control is a predictor of mortality in type II diabetic patients on maintenance hemodialysis. Nephrol Dial Transplant1997; 12: 2105–10.
7.
WhiteC.A., PilkeyR.M., LamM., HollandD.C.Pre-dialysis clinic attendance improves quality of life among hemodialysis patients. BMC Nephrol; 3: 3.
8.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837–53.
9.
TzamaloukasA.H., MurataG.H., ZagerP.G., EisenbergB., AvasthiP.S.The relationships between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J1993; 39: 880–5.
10.
PassadakisP., ThodisE., VargemezisV., OreopoulosG.Recommendations for glucose control in diabetics on CAPD. Int J Artif Organs1999; 22: 657–64.
11.
WongT.Y.H., ChanJ.C.N., SzetoC.C., LeungC.B., LiP.K.T.Clinical and biochemical characteristics of type 2 diabetic patients on CAPD: Relationship with insulin requirement. Am J Kidney Dis1999; 34: 514–20.
12.
JohanssonB.L., KernellA., SjobergS., WahrenJ.Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab1993; 77: 976–81.
13.
SmithD., DeFronzoR.A.Insulin resistance in uremia mediated by post binding defects. Kidney Int1982; 22: 54–62.
14.
KanounF., Ben AmorZ., ZouariB., Ben KhalifaF.Insulin therapy may increase blood pressure levels in type 2 diabetes mellitus. Diabetes Metab2001; 27: 695–700.
15.
SchwartzS., RaskinP., FonsecaV., GravelineJ.F.Effect of troglitazone in insulin treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med1998; 338: 861–6.
16.
HsuehW.A., JacksonS., LawR.E.Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care2001; 24: 392–7.
17.
WongT.Y., SzetoC.C., ChowK.M., LeungC.B., LiK.T.Combination treatment with rosiglitazone (RSG) reduces insulin requirement in type 2 diabetic patients on chronic ambulatory peritoneal dialysis (CAPD) (Abstract). Perit Dial Int2002; 72(suppl 2): S57.
18.
IshimuraE., NishizawaY., OkunoS., MatsumotoN., EmotoM., InabaM., KawagishiT., KimC.W., MoriiH.Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol1998; 11: 83–6.
19.
TakakuF., HirasimaK., OkinakaS.Effects of the bilateral section of splanchnic nerve in erythropoiesis. Nature1961; 191: 500–1.
20.
HarnettJ.D., KentG.M., FoleyR.N., ParfreyP.S.Cardiac function and hematocrit level. Am J Kidney Dis1995; 25(suppl): S3–7.
21.
FoleyR.N., ParfreyP.S., HarnettJ.D.Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int1995; 47: 186–92.
22.
HayashiT., SuzukiA., ShojiT., TogawaM., OkadaN., TsubakiharaY., ImaiE., HoriM.Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis2000; 35: 250–6.
HanssonL., ZanchettiA., CarruthersS.G., DahlofB., ElmfeldtD., JuliusS., MenardJ., RahnK.H., WedelH., WesterlingS.Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet1998; 351: 1755–62.
25.
LewisE.J., HunsickerL.G., ClarkeW.R., BerlT., PohlM.A., LewisJ.B., RitzE., AtkinsR.C., RohdeR., RazI., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001; 345: 851–60.
26.
Heart Outcomes Prevention Evaluation Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet2000; 22: 355: 253–9.
27.
WongT.Y., SzetoC.C., ChowK.M., ChanJ.C., LiP.K.T.Prognostic role of serum ACE activity on outcome of type 2 diabetic patients on chronic ambulatory peritoneal dialysis. Am J Kidney Dis2002; 39: 1054–6.
28.
StrozeckiP., AdamowiczA., NartowiczE., Odrowaz-SypniewskaG., WlodarczykZ., ManitiusJ.Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail2001; 23: 115–26.
29.
YamamotoT., OzonoK., MiyauchiA., KasayamaS., KojimaaY., ShimaM., OkadaS.Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis2001; 38(4 suppl 1): S161–4.
30.
KrakauerJ.C., McKennaM.J., BudererN.F., RaoD.S., WhitehouseF.W., ParfittA.M.Bone loss and bone turnover in diabetes. Diabetes1995; 44: 775–82.
31.
ZellerK., WhittakerE., SullivanL., RaskinP., JacobsonH.R.Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med1991; 324: 78–84.
32.
MeloniC., MorosettiM., SuraciC., PennafinaM.G., TozzoC., Taccone-GallucciM., CascianiC.U.Severe dietary protein restriction in overt diabetic nephropathy: Benefits or risks?J Ren Nutr2002; 12: 96–101.
33.
MehrotraR., NolphK.D.Low protein diets are not needed in chronic renal failure. Miner Electrolyte Metab1999; 24: 311–6.
34.
LeveyA.S., AdlerS., CaggiulaA.W., EnglandB.K., GreeneT., HunsickerL.G., KusekJ.W., RogersN.L., TeschanP.E.Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis1996; 27: 652–63.
35.
CaravacaF., ArrobasM., PizarroJ.L., EsparragoJ.F.Metabolic acidosis in advanced renal failure: differences between diabetic and non-diabetic patients. Am J Kidney Dis1999; 33: 892.
36.
ChauveauP., FouqueD., CombeC., LavilleM., CanaudB., AzarR., CanoN., AparicioM., LeverveX.Acidosis and nutritional status in hemodialyzed patients. French Study Group for Nutrition in Dialysis. Semin Dial2000; 13: 241–6.
37.
GrahamK.A., ReaichD., ChannonS.M., DownieS., GoodshipT.H.Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol1997; 8: 632–7.
